Siga technologies (siga) shares tumble after mpox therapy fails, chief medical officer terminated - hagens berman

Siga investors with losses encouraged to contact the firm san francisco, ca / accesswire / october 9, 2024 / biopharmaceutical company siga technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, tpoxx®, to treat mpox. hagens berman encourages siga technologies, inc. (nasdaq:siga) investors who suffered substantial losses to submit your losses now.
SIGA Ratings Summary
SIGA Quant Ranking